Checklist identification of candidates for systemic therapy in adult patients with atopic dermatitis in Germany: A multicentre study

Author:

Heratizadeh A.1ORCID,Mempel M.2,von Kiedrowski R.3,Hagl S.4,Mosch T.5,Fritz B.5,Werfel T.1

Affiliation:

1. Department of Dermatology and Allergy Hannover Medical School Hannover Germany

2. Hautarztpraxis Elmshorn Elmshorn Germany

3. Company for Medical Study & Service Selters GmbH (CMS) Selters Germany

4. formerly AbbVie Deutschland GmbH & Co. KG Wiesbaden Germany

5. AbbVie Deutschland GmbH & Co. KG Wiesbaden Germany

Abstract

AbstractBackgroundThe German S2k guideline is the first to include a checklist that captures atopic dermatitis (AD) signs and symptoms as well as the lack of treatment response to identify patients eligible for systemic therapy.ObjectivesIdentifying candidates for a start/switch of systemic therapy in adult AD patients in Germany by applying the S2k guideline's checklist.MethodsIn this German multicentre, cross‐sectional, non‐interventional study (German Clinical Trials Register number: DRKS00023296), adult patients with mild to severe AD were enrolled at dermatological outpatient clinics and offices between April and October 2021. Demographics, clinical characteristics and quality of life were collected using questionnaires during one single visit. Eligibility for a start/switch of systemic AD therapy was evaluated according to the criteria of the German S2k guideline's checklist.ResultsAtopic dermatitis patients (575) were included in the analysis. One hundred and sixty‐four patients (28.5%) received systemic (SYS) AD therapy and 411 patients (71.5%) did not (TOP). Of the TOP therapy patients, 38.7% were eligible to start systemic AD therapy, and about half of those (49.1%), were scheduled to start systemic AD therapy. The most frequent reason deciding against a systemic therapy was the patient's wish. Although 29.3% of SYS patients were eligible for a switch according to the criteria of the German S2k guideline's checklist, the majority (81.3%) did not switch AD therapy.ConclusionsThis is the first study on the implementation of the German S2k guideline's checklist in everyday care of AD patients in Germany. More than one‐third of the TOP patients were identified as eligible for systemic treatment. By applying the guideline's checklist criteria, another one‐third of SYS patients may have benefited from a change of current systemic therapy. The use of the German S2k guideline's checklist in routine care represents an important tool to ensure effective patient care and identify inadequately treated patients.

Funder

AbbVie Deutschland

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Reference26 articles.

1. Epidemiology of atopic dermatitis in adults: Results from an international survey

2. Atopic eczema: burden of disease and individual suffering – results from a large EU study in adults

3. New treatments in atopic dermatitis

4. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy

5. LangenbruchA RadtkeMA AugustinM ZanderN.Qualität der Neurodermitis ‐ Versorgung in Deutschland – Zwischenergebnisse der Studie AtopicHealth 2 poster presentation at DDG 2019 Berlin.https://doi.org/10.1007/s00105‐021‐04885‐3

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Quand mettre en route un traitement systémique dans la dermatite atopique ?;Annales de Dermatologie et de Vénéréologie - FMC;2024-06

2. Prävention und Gesundheitsförderung in der Dermatologie;Die Dermatologie;2024-04-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3